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Abstract
While much has been learned about how endothelial cells transform to mesenchyme during cardiac cushion formation, there remain
fundamental questions about the developmental fate of cushions. In the present work, we focus on the growth and development of cushion
mesenchyme. We hypothesize that proliferative expansion and distal elongation of cushion mesenchyme mediated by growth factors are the
basis of early valve leaflet formation. As a first step to test this hypothesis, we have localized fibroblast growth factor (FGF)-4 protein in
cushion mesenchymal cells at the onset of prevalve leaflet formation in chick embryos (Hamburger and Hamilton stage 20–25). Ligand
distribution was correlated with FGF receptor (FGFR) expression. In situ hybridization data indicated that FGFR3 mRNA was confined to
the endocardial rim of the atrioventricular (AV) cushion pads, whereas FGFR2 was expressed exclusively in cushion mesenchymal cells.
FGFR1 expression was detected in both endocardium and cushion mesenchyme as well as in myocardium. To determine whether the FGF
pathways play regulatory roles in cushion mesenchymal cell proliferation and elongation into prevalvular structure, FGF-4 protein was
added to the cushion mesenchymal cells explanted from stage 24–25 chick embryos. A significant increase in proliferative ability was
strongly suggested in FGF-4-treated mesenchymal cells as judged by the incorporation of 5-bromodeoxyuridine (BrdU). To determine
whether cushion cells responded similarly in vivo, a replication-defective retrovirus encoding FGF-4 with the reporter, bacterial -galac-
tosidase was microinjected into stage 18 chick cardiac cushion mesenchyme along the inner curvature where AV and outflow cushions
converge. As compared with vector controls, overexpression of FGF-4 clearly induced expansion of cushion mesenchyme toward the lumen.
To further test the proliferative effect of FGF-4 in cardiac cushion expansion in vivo (ovo), FGF-4 protein was microinjected into stage 18
chick inner curvature. An assay for BrdU incorporation indicated a significant increase in proliferative ability in FGF-4 microinjected
cardiac cushion mesenchyme as compared with BSA-microinjected controls. Together, these results suggest a role of FGF-4 for cardiac
valve leaflet formation through proliferative expansion of cushion mesenchyme.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
It is generally acknowledged that the endocardial epithe-
lium (endothelium) of specific segments of the primary
tubular heart transforms into prevalvular tissue called
“cushion mesenchyme” (Markwald et al., 1975, 1977; re-
viewed by Eisenberg and Markwald, 1995; Mjaatvedt et al.,
1999; Kisanuki et al., 2001). Although always presumed to
be the foundation of valve tissue, there is very little known
about how mesenchymalized cushions become mature valve
leaflets.
What is known is that two major cushion “pads” or
swellings project into the AV canal, the inferior and supe-
rior AV cushions, which fuse to form the AV septum. Based
on in vivo labeling, the septal leaflets for the mitral and
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tricuspid valves arise as luminal outgrowth from the AV
septum (de la Cruz et al., 1977; Lamers et al., 1995),
whereas their mural leaflets arise from two lateral AV cush-
ions which appear later in development (de la Cruz and
Markwald, 1998). In the proximal portion of the outflow
tract (OT), two large cushions (conal “ridges”) also expand
and fuse, but these cushions later become muscularized
(myocardialized) to form the muscular outlet septum and a
part of the posterior wall of the infundibulum (Qayyum et
al., 2002). Only cushions that develop in the distal outflow
tract (or truncus) form leaflets of the aortic and pulmonary
outlet valves (Bouchey et al., 1996; Markwald et al., 1998;
Qayyum et al., 2002). Thus, in the AV inlets and outlet
segments, cushion mesenchyme distally elongates, produc-
ing bulges that project into each lumen. The distribution of
proliferating mesenchymal cells is not uniform. For exam-
ple, subpopulations of cushion cells immediately adjacent to
the endocardium divide more rapidly than those at sites
close to the AV myocardium (de la Cruz and Markwald,
1998). This suggested to us that proliferation within the
cushion mesenchyme might produce the “force” for elon-
gation into the lumen. However, the mechanisms regulating
cushion expansion into the lumen have not been investi-
gated.
Secreted growth factors are reasonable candidates for
regulating these early events in valvulogenesis based on
their well known role in embryonic development. For ex-
ample, fibroblast growth factors (FGFs) belong to a struc-
turally related heparin-binding protein family that regulate
tissue differentiation and patterning, such as mesoderm for-
mation, neural induction, and patterning of the primary
body axis and limb mesoderm (see review by Szebenyi and
Fallon, 1999). It is well accepted that FGFs are potent
mitogens for endothelial and mesenchymal cells (Folkman
and Klagsbrun, 1987; Rifkin and Moscatelli, 1989; Gold-
farb, 1990; Gospodarowicz, 1991; Sugi et al., 1993, 1995;
Fig. 1. Double immunohistochemical localization of FGF-4 (FITC) and MF20 (RITC) in the stage 25 chick heart. (A) FGF-4 (indicated in green color) was
detected in the cushion mesenchymal cells (C) as well as in the myocardial cells (My), whereas, MF20 (indicated in red color) was localized only in
myocardial cells (My). (B) Higher power view shows punctate cytoplasmic staining of FGF-4 (green color) in both myocardial (My) and cushion
mesenchymal (C) cells. MF 20 staining (red color) appeared to be associated with myofibrillar structure in myocardial cells. (C) Section adjacent to that shown
in (A) in which antibodies (2 g/ml IgG) were preabsorbed with 100 g/ml immunogenic peptide. This treatment abolished FGF-4 staining, but MF 20
staining remained the same as seen in (A). (D) Higher power view of (C). Note that immunopreabsorption treatment prevented detection of the punctate
staining of FGF4 in the cushion mesenchymal cells.
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Cohn et al., 1995; Zhu et al., 1996; Choy et al., 1996; Dealy
et al., 1997). FGFs bind to and signal through low- and
high-affinity FGF receptors (FGFRs) (Szebenyi and Fallon,
1999). To date, four high-affinity FGF receptors have been
identified. They are structurally similar transmembrane re-
ceptor tyrosine kinases, and their extracellular portions con-
tain two or three immnoglobulin-like motifs (Ig loops) that
are important for ligand binding.
In the present study, we have localized mRNA of
FGFR1, 2, and 3, and FGF ligand, FGF-4, in developing
cardiac cushion tissue during the initial proliferative period
of early valvulogenesis. FGF-4 binds to all three of the
receptors except for a FGFR-IIIb splice variant. One signif-
icance of our findings is that expression of FGFRs correlates
well with the proliferative zones of AV cardiac cushion (de
la Cruz and Markwald, 1998). Based on in vivo expression
Fig. 2. Localization of FGF receptor messenger RNA expressions in stage 22 chick heart by in situ hybridization (dark field view). (A) FGFR1 expression
was detected throughout the heart, including myocardium and cushion mesenchyme. (C) FGFR2, however, was expressed intensely in the cushion
mesenchymal cells (arrows), but little signal was detectable in the myocardium. (E) Most strikingly, FGFR3 expression was confined to the endocardium of
the cardiac cushion (arrows). (A, C, E) Correspond to sections hybridized to antisense probes and (B, D, and F) sections hybridized to control sense probes.
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patterns, we hypothesize that FGF-4 modulates cardiac
cushion mesenchymal cell proliferation through FGFRs ex-
pressed in the cushion mesenchymal cells and overlying
endocardium. FGF-4/ embryos die on embryonic day
(ED) 5.0 (Feldman et al., 1995), while FGFR2-deficient
mice embryos die at ED 10-11 (Xu et al., 1998). Thus, these
mutant mice embryos die before or at the onset of valve
formation, which begins at around ED 10.5, making the
study of the roles of FGF-4 and/or FGFR2 in cardiac val-
vulogenesis difficult in these animal models. Therefore, in
our current work, we exogenously added or overexpressed
FGF-4 in avian cardiac cushion tissue to test our hypothesis.
Our data indicated that exogenous FGF-4 can promote pro-
liferation of AV cushion mesenchymal cells in culture and
in vivo (ovo), while virally supported, overexpression of
FGF-4 in cardiac cushion mesenchymal cells induced a
precocious expansion of cushion mesenchymal pads toward
and into the lumen. These results are the first to suggest a
potential role for a specific growth factor FGF-4 in signaling
cardiac valve leaflet formation.
Materials and methods
Chick embryos
Viral-free fertilized eggs of White Leghorn (Gallus gal-
lus domestics) chicken were purchased from Spafas (Pres-
ton, CN) and incubated in a humid atmosphere at 37.5°C.
Stages of embryonic development were determined by us-
ing the criteria of Hamburger and Hamilton (1951).
Immunohistochemical localization of FGF-4
Anti-FGF-4 antibody was purchased from Santa Cruz
Biotechnology, Inc. (Cat. No. sc-1361, Santa Cruz, CA). It
is an affinity-purified goat polyclonal antibody raised
against a peptide mapping at the carboxy terminus of the
FGF-4 of human origin (Taira et al., 1987), which is iden-
tical to corresponding mouse and rat sequences and has 83%
homology with corresponding chick sequences (Niswander
et al., 1994). Specificity of anti-FGF-4 antibody was tested
by Western blotting by the manufacturer. Anti-FGF-4 anti-
body reacts with FGF-4 of mouse, rat, and human origin. In
the present study, specificity of FGF-4 in immunostaining
of the chick embryonic tissue was verified by immunoab-
sorption. Anti-FGF-4 antibody was diluted to 1:100 (final
concentration of IgG was 2 g/ml) and preabsorbed with
100 g/ml immunogenic peptide (Santa Cruz, Cat. No.
sc-1962p) for 30 min at room temperature, followed by
clarification at 13,000g. This treatment abolished antibody
staining in chick tissue sections (Fig. 1).
Embryos were fixed in methanol at20°C overnight and
embedded in low melting temperature (50–54°C) paraffin,
Paraplast X-TRA, to preserve antigenicity. Embedded em-
bryos were stored at 20°C until sectioned at 5 m. Sec-
tions were deparaffinized with xylene and rehydrated in
decreasing ethanol series. After rinsing with distilled water
and phosphate-buffered saline (PBS, pH 7.2), the sections
were incubated at room temperature with 3% bovine serum
albumin (BSA)–PBS for 15 min to block nonspecific bind-
ing. Sections were then incubated with primary antibody,
anti-FGF-4 (1:100 in 1% BSA-PBS/0.02% NaN3), primary
antibody preabsorbed with immunogenic peptide as de-
scribed above or normal goat IgG (2 g/ml in 1% BSA–
PBS/0.02% NaN3) as a negative control in a humid chamber
at 4°C for 4–16 h. After rinsing with 1% BSA/PBS, FITC-
labeled rabbit anti-goat IgG (ICN Pharmaceuticals, Aurora,
OH) was applied for 1 h. For double immunostaining, MF20
(anti-sarcomeric myosin) immunostaining was performed
after FGF-4 immunostaining. The samples were rinsed and
incubated with MF20 followed by RITC-labeled secondary
antibody (ICN, Aurora, OH). The hybridoma for MF20 was
obtained from the Developmental Studies Hybridoma Bank.
After rinsing, samples were mounted in DABCO (Sigma,
St. Louis, MO) in 90% glycerol/PBS. Immunostained sec-
tions were examined under a Leica BMLB fluorescent mi-
croscope.
In situ hybridization of FGF receptors
Isolation for FGF receptor (FGFR)1, FGFR2, and
FGFR3 cDNA fragments from chick embryos and details of
the hybridization procedure were reported in a previous
communication (Szebenyi et al., 1995). Briefly, probes for
in situ hybridization were labeled with 35S[UTP] in vitro
transcription reactions (Promega, WI). The C-terminal half
of the third Ig loop of the FGFR1, 2, and 3 is encoded by
alternatively spliced exons resulting in either IIIb or the IIIc
splice variants. The probe we used in this study hybridizes
to both IIIb and IIIc variants of each FGFR (see previous
communication, Szebenyi et al., 1995). Chick embryos
Fig. 3. High-power view of FGFR3 mRNA expression in the cardiac
cushion tissue (bright-field view). This bright-field picture indicates re-
stricted pattern of FGFR3 mRNA expression to cushion endocardial en-
dothelial cells (arrows). Note that cushion mesenchymal cells have few
silver grains.
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(stages 14–27) were fixed with 4% paraformaldehyde in
PBS overnight. After rinsing with PBS in diethyl pyrocar-
bonate (DEPC)-treated water, embryos were dehydrated
through a graded series of methanol in PBS–0.1% Tween
(Ptw) and embedded in paraffin. Sections were cut at 7 m.
Pretreatment, hybridization, and washes of sections were
performed as previously described (Lyons et al., 1992),
except for a 45-min prehybridization step in a solution that
included 50% formamide, 0.3 M NaCl, 20 mM Tris–HCl
(pH 7.4), 5 mM EDTA, 10 mM sodium phosphate (pH 8.0),
10% dextran sulfate, 1 Denhardt’s, 0.5 g/ml total yeast
RNA, 10 mM dithiothreithol, and 250 nmol/ml adeonosine-
5-O-(thiotriphosphate) (Boeringer Mannheim, Indianapo-
lis, IN). The hybridization solution contained 50,000 cpm
probe/l of fresh prehybridization solution. Posthybridiza-
tion treatments included a 30-min incubation with RNase A
(20 g/ml) and washes in 50% formamide/2 SSC/10 mM
dithiothreitol (DTT) at 70°C, for 20 min before and after the
RNase digestion. This was followed by several washes in
2 SSC, 1 SSC, then 0.1 SSC at 37°C.
AV cushion mesenchymal cell culture and exogenous FGF
treatment
AV cushion tissues were dissected out from stage 24–25
chick embryos and dispersed with 0.25% trypsin-PBS at
37°C. Trypsinization was stopped by adding chick serum
(Sigma) to a final concentration of 10%. Dispersed cells
were resuspended in serum-free medium (SFM), medium
199 (Gibco/BRL, Grand Island, NY) supplemented with
ITS (insulin, transferrin, and selenium; Collaborative Re-
search), and 100 units/ml penicillin and 100 g/ml strepto-
mycin (Gibco/BRL). The dissociated cells were plated at the
density of 25,000 cells/well in eight-well Lab-Tek chamber
slides (Nunc) that had been precoated with fibronectin (bo-
vine plasma fibronectin; Sigma). After attachment of the
cells to the well, medium was replaced with SFM or recom-
binant human FGF-4 (R&D Systems, Minneapolis, MN) in
SFM at final concentrations of 10, 25, 50, 100, or 250 ng/ml.
FGF-4 protein is conserved among species, and the recom-
binant human FGF-4 acts as a differentiation inducer in
Fig. 4. Exogenously added FGF-4 stimulates BrdU incorporation by cardiac cushion mesenchymal cells in culture. Cushion mesenchymal cells were from
stage 20–25 chick AV canal region and were cultured with serum-free-defined medium (SFM; medium 199 supplemented only with insulin, transferrin, and
selenium) or SFM containing added FGF4 (50 ng/ml). FGF4 (50 ng/ml in SFM) was added daily. After 48 h, cultures were treated with 50 M
5-bromodeoxyuridine (BrdU) for the last 2 h of the culture period, followed by fixation and immunostaining using an anti-BrdU monoclonal antibody. Note
that the increased incidence of BrdU-positive (green) nuclei in the FGF4-treated culture (D) compared with the control culture with SFM (B). (A, C) Phase
contrast photomicrograph.
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chick mesoderm culture (Zhu et al., 1996). Mesenchymal
cells were observed daily by using Hoffman optics, and the
effect of added growth factors were evaluated at 48 h of
culture.
BrdU incorporation assay in cultured cushion
mesenchymal cells
5-bromodeoxyuridine (BrdU; Sigma) was added to a
final concentration of 50 M for 2 h before the termination
of the culture. Mesenchymal cells were rinsed with PBS,
fixed with ice-cold 100% ethanol, and rehydrated in de-
creasing ethanol series. Immunohistochemistry to assess
BrdU incorporation was described previously (Sugi et al.,
1993). Briefly, after rinsing with PBS, cultured cells were
incubated in 2 N HCl containing 0.5% Tween 20 for 8 min
at 37°C, washed with 0.5% Tween 20/PBS, and incubated
in a 1:2.5 dilution of monoclonal anti-BrdU (Becton-Dick-
inson. Cat. No. 7580) for 1 h at room temperature. After
rinsing with PBS, the cells were stained with FITC-conju-
gated goat anti-mouse IgG (ICN, Aurora, OH) for 30 min at
room temperature. Lastly, to stain all nuclei in the mesen-
chymal cells, 0.1 g/ml propidium iodide (Molecular
Probes) in distilled water (DW) was added for 1 min. After
rinsing with DW, the cells were mounted in DABCO
(Sigma) in 90% glycerol/PBS and examined under a Zeiss
Axioscope.
Propagation of virus
The retroviruses used for the present study are replica-
tion-defective variants of the spleen necrosis virus. Con-
struction of the viral vectors and propagation of the virus
have been described previously (Mima et al., 1995a,b; Mi-
kawa, 1995; Itoh et al., 1996). Briefly, after removal of
polyadenylation signals, the cDNA of FGF4 was inserted
between the 5LTR and a bacterial -galactosidase (-gal)
gene of a vector plasmid, pSNZ (Mikawa et al., 1992). As
a negative control, a retrovirus CXL (Mikawa et al., 1991)
expressing only -gal was used. Each viral construct was
transfected into packaging cells, D17.2G. After propagating
recombinant viruses, 108 virions/ml for CXL and FGF-4
were obtained on average from ultracentrifugation/concen-
tration of the supernatant of the virus-producing packaging
cells. The biological activities of the FGF-4 virus have been
examined by infecting somatic mesoderm, mesenchyme in
limb bud, cardiogenic mesoderm and coronary vascular
cells, and assaying the effects on morphology, differentia-
tion, and cell proliferation as described (Mima et al.,
1995a,b; Mikawa, 1995; Ito et al., 1996).
Microinjection of virus and morphological analysis
A small window of less than 5 mm diameter was opened
in the shell at the blunt end of the egg, and the underlying
shell membrane was removed. Embryos were staged after
introducing biologically inert dye, India ink (5% in Ty-
rode’s solution), beneath the embryos. Viruses were micro-
injected into the cushions developing along the inner cur-
vature at stages 17–18. At these stages, the superior AV
cushion (SAVC) and the sinistroventral conal cushion
(SVCC) merge along the inner curvature but do not nor-
mally form luminal expansions until stages 25–28. Virus
solutions of 1–5 nl containing 100 g/ml of polybrene were
pressure injected into the cushion mesenchyme in ovo under
the control of Picospritzer II (General Valve Co., NJ). After
the eggs were resealed with Parafilm, each injected embryo
was returned to a humidified incubator at 37.5°C and incu-
bated for 2 additional days (approximate stages 23–25).
Embryos were harvested and fixed with 2% paraformalde-
hyde in PBS at 4°C overnight. Embryos were then rinsed
with PBS at 4°C and processed in whole mount for 5-
bromo-4-chloro-3-indolyl -D-galactopyranoside (X-gal)
histochemistry overnight, as previously described (Mikawa
et al., 1992). After taking whole-mount images under a
stereomicroscope, MZ12 (Leica) equipped with digital mi-
croscope camera (Polaroid), embryos were subsequently
embedded in paraffin and serially sectioned at 5–6 m
thickness. Sections were deparaffinized, counterstained with
nuclear fast red, and observed under a light microscope,
Axioscope (Zeiss).
Microinjection of FGF-4 protein and morphological
analysis
Chick embryos were prepared in the same way as de-
scribed for the virus injection study. Recombinant human
FGF-4 was microinjected into the cushions developing
along the inner curvature at stages 17–18. One to five
nanoliters of FGF-4 solutions (50 g/ml) with 0.1% BSA
(carrier protein) in PBS or control BSA (0.1%) in PBS were
pressure injected into the cushion mesenchyme in ovo under
the control of Picospritzer II (General Valve Co., NJ). Em-
bryos were resealed and incubated another 18 h. Ten mi-
crograms of BrdU/200 l Tyrodes were topically applied to
the embryos for 3 h before the termination of the incubation
following the methods published elsewhere (Sedmera et al.,
2002). Embryos were harvested and fixed with cold 100%
Methanol overnight, embedded in paraffin, and serially sec-
tioned at 6 m thickness in sagittal planes. Four serial
sections were mounted on each slide, and slides were seri-
ally numbered. From each sample, sections spanning the
entire proximal–distal lengths of the injected cushions were
carefully selected under light microscope, and odd-num-
bered slides (4–5 slides from each sample) were subjected
for immunofluorescent microscopy and quantitative evalu-
ation of BrdU incorporation. Sections were deparaffinized
and immunostained with MF20 followed by Cy5-conju-
gated donkey anti-mouse IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA). Sections were then incu-
bated in 2 N HCl containing 0.5% Tween 20 for 30 min at
room temperature, washed with 0.5% Tween 20/PBS, and
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incubated in a 1:2.5 dilution of monoclonal anti-BrdU (Bec-
ton-Dickinson. Cat. No. 7580) for 1 h at room temperature.
After rinsing with PBS, the sections were stained with
FITC-conjugated goat anti-mouse IgG (ICN, Aurora, OH)
for 1 h. Lastly, to stain all nuclei, 0.1 g/ml propidium
iodide (Molecular Probes) in distilled water was applied for
1 min. After rinsing and mounting in DABCO (Sigma) in
90% glycerol/PBS, sections were examined under a Leica
TCS SP2 AOBS confocal microscope.
Results
Immunohistochemical localization of FGF-4 at the onset
of valve formation
FGF-4 protein expression in myocardial precursors and
developing myocardial cells has previously been demon-
strated in chick hearts from stages 5 to 27 (Zhu et al., 1996).
Our present work focuses on cardiac cushion mesenchymal
cells and their antecedent, endocardial endothelial cells
along the inner curvature of the heart at the onset of valve
formation (reviewed in Mjaatvedt et al., 1999). In agree-
ment with Zhu et al. (1996), we found that FGF-4 was
localized in atrial and ventricular myocardium throughout
all stages (14–27) examined, including AV myocardium
adjacent to the forming AV cardiac valves (Fig. 1A and B).
Cytoplasmic expression of FGF-4 was detected in AV and
OT cushion mesenchymal cells as well as AV endocardial
endothelial cells (Fig. 1B). Immunostaining of FGF-4 was
abolished by preabsorption of the FGF-4 antibody with
immunogenic peptide as described in Materials and meth-
ods (Fig. 1C and D), which verified specificity of FGF-4
immunostaining in chick embryos.
Spatial expression patterns of FGFR1, 2, and 3 at the
onset of cardiac valve formation
In situ hybridization was performed to examine the
expression of FGFR1, 2, and 3 transcripts prior to and
after the onset of cardiac valve formation (i.e., stages 18
vs 25–26). We specifically focused on the AV canal
region of the inner curvature. Regarding the FGFRs, all
stages examined exhibited similar patterns of expression.
Fig. 2 indicates FGFR1, 2, and 3 expression patterns in a
stage 23 chick heart. FGFR1 mRNA was distributed
throughout the heart, including epicardium, myocardium,
endocardium, and cardiac cushion mesenchyme (Fig.
2A). Note that, even though FGFR1 was expressed
throughout the heart, expression in the cushion mesen-
chyme appeared higher than in any other tissue of the
heart. Unlike FGFR1, both FGFR2 and FGFR3 exhibited
distinctive regional expression patterns in the heart.
FGFR2 mRNA was exclusively expressed in the AV
cushion mesenchyme with little expression found in the
myocardium (Fig. 2C, arrows). Most strikingly, FGFR3
mRNA expression was restricted primarily to AV endo-
cardial endothelial cells (Fig. 2E) with little, if any,
expression in the AV cushion mesenchymal cells (Fig. 3).
Fig. 5. Quantitative analysis of exogenous FGF-4 mediated proliferation. BrdU-positive and -negative nuclei in the cultured AV cushion mesenchymal cells
were counted to determine the percentage of cells in cell-cycle transit. A total of 500 nuclei in each culture well was evaluated in random fields. Vertical
bars indicate1 SD of the mean. Six wells of mesenchymal cells were evaluated for each dosage of the culture. FGF-4 (as low as 10 ng/ml in SFM) promoted
proliferation of mesenchymal cells. The asterisk indicates a significant difference at the 1% level of confidence using Student’s t test.
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Effect of exogenously added FGF-4 on BrdU
incorporation by cultured cardiac cushion
mesenchymal cells
To determine whether FGF-4 exerted an effect on AV
cushion mesenchymal cell proliferation, we added FGF-4 to
the medium of cultured AV cushion mesenchymal cells.
Just prior to the onset of valve leaflet formation, AV cushion
mesenchymal cells at stages 24–25 were dissociated by
trypsinization and cultured in SFM (medium 199 supple-
mented only with insulin, transferrin, and selenium) with or
without FGF-4. As indicated in Fig. 4, mesenchymal cells
grow well in SFM alone without serum supplement. Final
concentrations of 10, 25, 50, 100, or 250 ng/ml FGF-4 were
added daily to test dose-dependence effects. After 48 h, the
culture received 50 M 5-bromodeoxyuridine (BrdU;
Sigma) for the last 2 h of the culture period. The percentage
of nuclei that contained BrdU indicates the percentage of
the cells entering S-phase of the cell cycle, which provides
an index of proliferation activity. As little as 10 ng/ml of
FGF-4 caused a statistically significant, 50% increase in the
proliferative activity of mesenchymal cells (Fig. 5).
Microinjection of FGF-4 retrovirus into cushion tissue
To evaluate the effect of FGF-4 on cardiac valve forma-
tion in vivo, FGF-4 retrovirus was pressure injected at
stages 17–18 into the cushions of the inner curvature of the
heart and embryos were further incubated to reach stage
23–25. At these stages, the inner curvature is completely
lined with cushion tissue that formed by merging of the
SVCC and the SAVC (Markwald et al., 1998), but luminal
expansions have not normally begun (de la Cruz and Mark-
wald, 1998). Replication-defective retovirus, variants of the
spleen necrosis virus, pSNZ (Mikawa et al., 1992) was
generated to express both FGF-4 and -galactosidase
(Mima et al., 1995a, 1995b; Mikawa, 1995). Therefore,
virus-infected, FGF-4-secreting cells are detectable by X-
gal histochemistry for -galactosidase. Another virus that
expressed only -galactosidase (-gal) was used as a con-
trol. Cardiac mesenchymal cells infected in vivo with
FGF-4 virus indicated dense populations of -gal viral
marker-positive cells detected in the paraffin sections (blue
color in Fig. 6B) and expansion of mesenchyme into the
lumen (arrow in Fig. 6A), suggesting proliferative expan-
sion of the cushion. Control -gal virus when injected into
cushion mesenchyme showed normal development (Fig.
6C). A total of 17 chick embryos were successfully micro-
injected with virus as judged by formation of -galactosi-
dase-positive colonies confined to cardiac cushions. Eight
out of 17 embryos were microinjected with FGF-4  -gal
virus, and 9 were microinjected with control -gal virus.
None of the 9 -gal virus-microinjected embryos showed
any luminal expansion of cushion mesenchyme. Seven out
of 8 of the FGF-4  -gal virally injected embryos clearly
demonstrated luminal expansion of -gal-positive cushion
mesenchyme. Similar morphological changes were found in
both SVCC and SAVC mesenchyme.
Microinjection of FGF-4 protein into cushion tissue
To further evaluate the in vivo effect of FGF-4 on cardiac
cushion mesenchymal cell proliferation, recombinant hu-
man FGF-4 protein was pressure injected into the cushions
of the inner curvature at stages 17–18. Embryos were re-
sealed and incubated another 18 h to reach stages 19–20.
Eighteen hours of treatment were chosen for the in ovo
assay since biological effects of administered FGFs have
been previously reported with this time flame (8–30 h)
(Alsan and Schultheiss, 2002; Vogel and Tickle, 1993).
BrdU was topically applied to the embryos for 3 h before
the termination of the incubation. BrdU incorporation into
the nuclei appeared to occur evenly in all parts of the
embryos (not shown). As shown in Fig. 7B, FGF-4-injected
cushion mesenchyme had a significant increase in the per-
centage of BrdU-labeled mesenchymal cells (indicated by
the yellow color in Fig. 7), including those seen in cushions
that protruded toward the lumen as compared with BSA-
injected control (Fig. 7A). Quantitative evaluation of the
BrdU incorporation assay shows that FGF-4 microinjection
into the cushion tissue caused a statistically significant in-
crease in BrdU incorporation of mesenchymal cells as com-
pared with BSA-injected controls (Fig. 8). Moreover, BSA-
injected control samples tended to show more BrdU-
positive cells near the luminal surface of the cushion, while
FGF-4-injected samples show more BrdU-positive cells in
the central part of the cushion, which suggests that FGF-4
injection altered (expanded) the normal distribution of
BrdU-positive cells. These data clearly support the hypoth-
esis that FGF-4 can induce expansion of the cushion mes-
enchyme through proliferation of cushion mesenchymal
cells in vivo (ovo).
Discussion
It has been always presumed that cardiac cushion mes-
enchyme is “remodeled” into valve tissue. However, little is
known as to how cushions form mesenchymal expansions
that progressively project into the lumen and subsequently
differentiate into mature valvular tissue. Based on morpho-
logical studies (de la Cruz and Markwald, 1998), we pro-
pose that the following morphogenetic steps sequentially
serve to transform a primitive cushion pad into an elongated
and radially attenuated leaflet: (1) distal outgrowth, elonga-
tion, and spreading of cushion mesenchyme upon a substra-
tum of ventricular myocardium (Oosthoek et al., 1998), (2)
differentiation of multipotential cushion cells into fibroblas-
tic/myofibroblastic tissue (Icardo and Colvee, 1995), and
finally, (3) “delamination” of the leaflets from the associated
ventricular myocardium, creating in the process both free
edges and a persisting supportive, suspensory apparatus (de
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Fig. 6. FGF-4 overexpression induces expansion of cardiac cushion mesenchyme in ovo. Replication-defective retrovirus encoding FGF-4 and bacterial
-galactosidase (FGF-4  -gal) or -galacosidase (-gal) was microinjected into the sinistroventral conal cushion (SVCC) of the heart of stage 17 chick
embryos. Whole embryos were incubated to stage 24, then processed with X-gal histochemistry to detect viral reporter -galactosidase expression. A total
of 17 chick embryos were successfully microinjected with virus only into cardiac cushions. Eight out of 17 embryos were FGF-4 -gal virus microinjected,
and 9 of them were -gal-microinjected. None of 9 -gal-microinjected embryos showed expansion of cushion mesenchyme. Seven out of 8 FGF-4  -gal
virus-injected embryos clearly demonstrated luminal expansion of -gal-positive cushion mesenchyme. (A) The arrow indicates intense viral -galactosidase
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la Cruz and Markwald, 1998; Oosthoek et al., 1998). The
present work focuses on what we believe must be a part of
the initial step in these valvulogenic processes, the distal
outgrowth of cushion mesenchyme into the lumen of the
primary heart tube.
Because the initial expansion of cushions resembles that
of limb buds, we considered that an analogy to limb mor-
phogenesis might provide clues as to the molecular candi-
dates that could serve to initiate the formation of prevalvular
leaflets. In this paper, we focus on FGFs, which are known
mitogens for limb mesoderm that play a key role in the
distal expansion of the limb buds (reviewed by Szebenyi
and Fallon, 1999). Recent work using conditional disruption
of FGF-8 in mice indicated that inactivating FGF-8 in early
limb ectoderm caused a reduction in limb-bud size, altered
expression of sonic hedge hog (shh), bone morphogenetic
protein (BMP)-2, and other FGF genes, such as FGF-4
(Lewandoski et al., 2000; Moon and Capecchi, 2000).
FGF-4 knockout mice die at ED 5, indicating the impor-
tance of FGF-4 signaling during early morphogenesis (Feld-
man et al., 1995). More recently, conditional inactivation of
FGF-4 using Msx2-cre mouse indicated that the mice sur-
vive longer and formed limbs in the absence of FGF-4 (Sun
et al., 2000). However, these recent findings did not shed
much light on the role of FGF-4 in cushion and valve
morphogenesis because Msx2-cre mouse is based on a pu-
tative limb-specific Msx2 regulatory element in the Msx2
promoter, and moreover, Msx2 is expressed mostly in AV
and OT myocardium not in the cushion mesenchyme, which
express Msx-1 (Chan-Thomas et al., 1993).
FGF signaling pathways are also known to be intricate
and intertwined with other regulatory molecules, e.g., insu-
lin-like growth factor (IGF), transforming growth factor
(TGF)-, BMP and vertebrate homologue of Drosophila
wingless activated pathways (reviewed by Szebenyi and
Fallon, 1999). Interaction of FGFs and BMPs has been
proposed in limb formation (Dahn and Fallon, 1999; Moon
and Capecchi, 2000). FGF-4 and BMP-2 appear to have
opposite effects on limb distal growth (Niswander and Mar-
tin, 1993). For example, inhibiting BMPs induced FGF-4
expression and established a shh/FGF4 feedback loop in
regulating limb bud formation (Zuniga et al., 1999). BMP-2
transcripts (Lyons et al., 1990) are known to be expressed in
AV myocardial cells prior to endocardial to mesenchymal
transformation at ED 8.5–9.0 in mice. BMP-2 protein is also
localized in AV and OT cushion mesenchymal cells at ED
10.5–16, (unpublished data). Our present work indicated
that FGF-4 was expressed in cushion mesenchymal cells in
the chick (Fig. 1), that exogenously added FGF4 induced
proliferation of cushion mesenchymal cells in vitro (Figs. 4
and 5) and in vivo (ovo) (Figs. 7 and 8), and that FGF-4
overexpression induced precocious extension of cushion
mesenchyme into the lumen (Fig. 6), indicating a role of
FGF pathway in early leaflet formation. However, it re-
mained to be determined whether FGFs also interact with
staining in the heart (indicated in blue color). (B) A paraffin section of the same embryo shows the outgrowth of a bud-like expansion of cushion tissue stained
with X-gal. (C) Control embryos infected with CXL virus encoding only bacterial -galactosidase did not show this extra outgrowth from the cushion tissue.
Fig. 7. FGF-4 protein injection stimulates BrdU incorporation by cardiac cushion mesenchymal cells in ovo. Recombinant human FGF-4 was microinjected
into cushion mesenchyme of the inner curvature at stages 17–18. Embryos were incubated another 18 h to evaluate the proliferative effect of FGF-4. BrdU
was applied topically to the embryo for 3 h before the termination of the incubation in ovo. After the fixation and paraffin embedding, sections were
immunostained with an anti-BrdU monoclonal antibody (indicated as green color). Myocardium was immunostained with MF 20 (indicated as blue color),
and all nuclei were stained with propidium iodide (red color). Note that the increased incidence of BrdU-positive (yellow color, after overlay of triple labeled
immunofluorescent microphotographs) nuclei in the FGF-4-injected cushion mesenchyme (B) as compared with the BSA-injected control (A). BSA-injected
control samples tends to show more BrdU-positive cells near the luminal surface of the cushion (A), while FGF-4-injected samples shows more BrdU-positive
cells in the central part of the cushion (B).
Fig. 8. Quantitative analysis of FGF-4 protein mediated cardiac cushion
mesenchyme proliferation in ovo. Six-micrometer serial paraffin sections at
every 24 m were subjected for quantitative evaluation of BrdU incorpo-
ration into nuclei as an index of proliferation. BrdU-positive and -negative
nuclei in cushion mesenchymal cells were counted to determine the per-
centage of cells, which were in cell-cycle transit. Vertical bars indicate 1
SD of the mean. BrdU incorporation in FGF-4-microinjected samples is
statistically higher than that in the control BSA-injected cushion mesen-
chyme. The asterisk indicates a significant difference at the 1% level of
confidence using Student’s t test. Numbers of chick embryos used for
quantitative evaluation were indicated in the parentheses.
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other candidate regulatory molecules, such as BMPs, to
regulate/coordinate mesenchymal cell proliferation and/or
differentiation and gene expression necessary for further
differentiation of cushions into valve leaflets.
Our in situ hybridization data for localizing FGF recep-
tors also support a signaling role for FGF ligands in valvu-
logenesis. Specifically, our findings indicate a spatially re-
stricted pattern for FGFR expression in AV cushion tissue
(Figs. 2 and 3). The expression of FGFRs correlated well
with the proliferative zone previously seen in AV cardiac
cushion. While FGFR1 expression was detected throughout
the heart at all stages examined (stages 14–27), FGFR2 was
confined to just the cushions in the heart. Most striking,
however, was FGFR3, whose expression was uniquely re-
stricted to the endocardium overlying the cushions. It is
presently unclear how these distinctively restricted patterns
of expression for FGF receptors might interact to regulate
various phases of early valvulogenesis, particularly FGFR3.
It is possible that this receptor merely serves to keep the
endocardium growing at a pace commensurate with cushion
mesenchymal growth. Yet, the similarity of FGFR3 expres-
sion to that of nuclear factor of activated T cells (NFATc1)
may suggest another role more akin to that of limb ectoder-
mal epithelium (particularly that of the apical ridge) which
is known to inductively interact with the adjacent limb
mesoderm/mesenchyme. NFATc1 is exclusively expressed
in endocardial cells but does not appear to play a role in the
transformation of the endocardium into cushion mesen-
chyme (Ranger et al., 1998; de la Pompa et al., 1998).
Rather, in mutant mice deficient for this transcription factor,
the mesenchymalized cushions fail to initiate elongation
into prevalvular leaflets and death occurs at ED 14 or 15.
How NFATc1 deficiency disrupts cushion valvulogenesis is
not known. If early valvulogenesis shares any similarities to
early limb bud outgrowth, then one possibility is that the
endocardium following FGF signaling secretes a paracrine
signal that initiates or sustains cushion elongation. Thus,
spatially and temporally restricted FGFR3 signaling of
cushion endocardium may be linked in some unknown way
to the mechanisms whereby endocardial upregulation of
NFATc1 imparts an endocardial morphogenetic influence
on the mesenchymalized primordia for future valvular leaf-
lets. In addition to simply promoting proliferation, it will be
of interest to know how FGF signaling modulates or inter-
acts with other regulatory molecules to potentially regulate
further morphological changes in valve formation, such as
delamination from myocardium, differentiation into myofi-
broblastic lineage, or formation of the supporting tension
apparatus.
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